Prescriby

Cover Block

PUBLIC

Field	Value
Name	Prescriby
Tagline	Digital platform improving prescription safety and monitoring to prevent opioid addiction
Headquarters	Reykjavik, Iceland (with Canadian operations)
Founded	2019
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe / North America
Growth Profile	Venture Scale
Funding Label	Seed
Total Disclosed	~$2,100,000

Links

PUBLIC

• LinkedIn: https://is.linkedin.com/company/prescriby

Executive Summary

PUBLIC

Prescriby is an Icelandic-Canadian healthtech company building a prescription management platform aimed at preventing opioid dependence at the point of prescribing rather than treating addiction after the fact [EU-Startups, April 2024]. Founded in 2019 by Kjartan Thorsson, the company sits at the intersection of two policy priorities that continue to draw public capital and clinical attention: the opioid crisis in North America and tighter prescribing protocols in European health systems [ArcticStartup]. The product, as described in public profiles, combines a treatment generator with a dashboard monitor designed to simplify clinical decision-making around addictive medications [Crunchbase]. In April 2024 the company closed a $2.1 million seed round led by Crowberry Capital, with participation from investors in Canada, Denmark, and Iceland [Northstack] [EU-Startups, April 2024]. The business model appears to follow a clinic-facing SaaS pattern, and Prescriby has reportedly established a tapering clinic in Maine, suggesting a hybrid software-and-service approach to early commercialization [Mainebiz]. Over the next 12 to 18 months, the questions worth tracking are whether the company can convert pilot clinic deployments into recurring revenue, how it manages cross-border regulatory exposure across Iceland, Canada, and the United States, and whether the seed capital is enough to reach a credible Series A milestone in a category where reimbursement pathways remain fragmented.

Data Accuracy: GREEN -- Confirmed by EU-Startups, ArcticStartup, Northstack, and Crunchbase.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech (prescription safety, addiction prevention)
Technology Type	Software (Non-AI)
Geography	Iceland HQ, Canadian operations, US pilot footprint
Growth Profile	Venture Scale
Founding Team	Kjartan Thorsson (founder)
Funding	Seed, ~$2.1M disclosed

Company Overview

PUBLIC

Prescriby was founded in 2019 and operates as an Icelandic-Canadian entity, with public coverage describing the team as straddling Reykjavik and Canada [PitchBook] [ArcticStartup]. The premise, articulated repeatedly across public coverage of the seed round, is that the most effective intervention point for opioid dependence is upstream of addiction itself: at the moment a clinician writes the prescription and during the tapering window that follows [EU-Startups, April 2024]. That framing distinguishes Prescriby from the larger and better-funded category of addiction treatment platforms, which engage patients only after dependence has formed.

The most concrete commercial milestone in the public record is the April 2024 seed round of $2.1 million, led by Nordic firm Crowberry Capital with participation from investors across Canada, Denmark, and Iceland [Northstack] [EU-Startups, April 2024]. Around the same period, regional press in the United States reported that Prescriby had set up a tapering clinic in Maine, indicating the company is testing a clinical service layer alongside its software product [Mainebiz]. Maine has been one of the US states most affected by opioid mortality, which makes it a logical, if demanding, beachhead market.

Beyond the funding announcement and the Maine clinic reference, the company's public footprint remains thin, which is consistent with its seed stage. Customer counts, prescriber counts, and revenue figures are not publicly available. Investors evaluating the company will need to source those directly.

Data Accuracy: GREEN -- Confirmed by EU-Startups, Northstack, ArcticStartup, PitchBook, and Mainebiz.

Product and Technology

MIXED

Prescriby's product, as described in third-party databases, is built around two components: a treatment generator that helps clinicians construct tapering and prescribing plans for addictive medications, and a dashboard monitor that tracks patient progress and surfaces risk signals to the prescribing clinic [Crunchbase] [PUBLIC]. The company's LinkedIn page positions the product as "the first data driven treatment management platform for addictive medication" [LinkedIn] [PUBLIC]. Both descriptions point to a workflow tool sitting alongside, rather than inside, the electronic health record, though the exact integration model is not detailed in public sources.

The focus on tapering, the structured reduction of dosage over time, is a meaningful product choice. Tapering protocols are clinically complex, vary by drug and patient history, and are an area where many community clinics lack standardized tooling. A software layer that codifies tapering schedules, monitors adherence, and alerts clinicians to red flags addresses a workflow gap rather than competing head-on with EHR vendors. The Maine tapering clinic suggests Prescriby is using a directly-operated clinical site to refine the protocol library and gather outcomes data that would be difficult to obtain through software-only deployments [Mainebiz] [PUBLIC].

On the technology stack, Prescriby is classified as Software (Non-AI) in the structured profile, and there is no public claim of a proprietary machine learning model. The differentiation, on the available evidence, rests on clinical protocol design and prescriber workflow rather than on a model layer. That is a defensible posture in a regulated category where explainability matters, though it also means the moat will need to come from clinical evidence, integrations, and prescriber adoption rather than from algorithmic novelty.

Data Accuracy: YELLOW -- Product descriptions corroborated across Crunchbase and LinkedIn, but specific feature depth and integration partners are not independently verified.

Market Research and Opportunity

PUBLIC

The market for prescription opioid management sits inside a public health emergency that has driven a decade of regulatory, reimbursement, and litigation activity across North America. The clinical and policy consensus has shifted decisively toward prevention and responsible prescribing, which is the precise lane Prescriby occupies [EU-Startups, April 2024].

Demand drivers are well documented in the cited coverage: opioid-related mortality remains elevated in the United States and Canada, state and provincial health authorities have introduced prescription drug monitoring programs, and payers are increasingly receptive to tools that demonstrate reduced long-term opioid utilization [ArcticStartup]. European health systems, including those in the Nordics, have taken a more conservative prescribing posture historically, but coverage of the Prescriby round notes that addictive-medication oversight is a growing concern across European primary care as well [EU-Startups, April 2024]. The company's cross-border footprint, Iceland for product development and Canada and the US for clinical deployment, aligns with where the regulatory pressure and the clinical need diverge most sharply.

Adjacent and substitute markets include addiction treatment platforms (medication-assisted treatment providers, telehealth recovery services), prescription drug monitoring program software sold to state agencies, and clinical decision support modules embedded in electronic health records. Each of these is a distinct buyer with a distinct procurement cycle, and Prescriby's positioning as an upstream prevention tool gives it a different sales narrative than the post-addiction treatment market it is often grouped with in coverage. The risk in any of these adjacencies is that an EHR vendor decides to ship a competing module natively, which would compress the standalone software opportunity.

Regulatory and macro forces cut both ways. Tighter prescribing rules and litigation settlements (notably the multi-state opioid settlements in the US) are channeling funds toward exactly the kind of intervention Prescriby is selling, which is a tailwind. At the same time, healthcare procurement cycles are slow, cross-border data and clinical certification requirements are non-trivial, and reimbursement codes for prevention software remain underdeveloped in most jurisdictions.

Sizing claim	Value	Source
Seed round size	$2.1M	[EU-Startups, April 2024]
Founding year	2019	[PitchBook]

The public record contains no third-party TAM estimate specific to opioid-prevention SaaS, so analytically the opportunity has to be triangulated from the broader addiction treatment and clinical decision support categories rather than from a named report. The most useful read on demand, for now, is the willingness of a Nordic specialist fund and a cross-border syndicate to back the company at seed.

Data Accuracy: YELLOW -- Demand drivers corroborated across EU-Startups and ArcticStartup, but no third-party TAM figure is publicly cited.

Competitive Landscape

MIXED

Prescriby is positioned as a prevention-first tool in a category dominated by post-addiction treatment platforms and broad clinical decision support vendors, which is both its differentiation and its commercial challenge.

The public sources reviewed for this report do not name a direct competitor to Prescriby [PUBLIC]. That absence is itself informative: it suggests either that the prevention-at-prescribing niche is genuinely underserved by venture-backed software, or that competitors exist as features within larger platforms (EHRs, prescription drug monitoring program vendors) rather than as standalone companies that show up in startup databases. Both interpretations are plausible, and both have implications for how Prescriby should be evaluated.

On the segment-by-segment map, the competitive set breaks into three groups. First, addiction treatment platforms, including the medication-assisted treatment telehealth providers that have raised substantial venture capital over the past five years, address patients after dependence is established and would only compete with Prescriby if they extended upstream into prescriber workflow. Second, clinical decision support modules inside EHR systems (Epic, Cerner, and regional equivalents) can theoretically deliver tapering guidance natively, and represent the most credible long-term squeeze on a standalone tool. Third, prescription drug monitoring program software sold to state and provincial health authorities operates on a different sales motion (government procurement) but addresses an overlapping problem space.

Where Prescriby has a defensible edge today is in clinical specificity and the operational data it can generate from its own Maine tapering clinic [Mainebiz] [PUBLIC]. Running a clinic, rather than only selling software, is capital-intensive but produces outcomes data that an EHR module would struggle to match without a similar investment. That data, if it translates into peer-reviewed evidence of reduced long-term opioid utilization, is the kind of asset that becomes hard to replicate. Where the company is most exposed is distribution: it does not own the prescriber relationship the way an EHR does, and clinic-by-clinic sales in healthcare is famously slow.

The most plausible 18-month competitive scenario has Prescriby winning if a US state health authority or a Canadian provincial payer adopts the platform as part of an opioid settlement-funded program, which would give it a defensible reference customer and a procurement template. The losing scenario is one in which a major EHR vendor releases a tapering module bundled into existing contracts before Prescriby has accumulated enough outcomes evidence to justify a separate purchase order.

Data Accuracy: YELLOW -- Competitive framing is analytical; no direct named competitor appears in the cited public record.

Opportunity

PUBLIC

If Prescriby executes, the prize is becoming the default clinical workflow layer for prescribing and tapering addictive medications across North American and European primary care.

The headline opportunity. The single largest outcome available to Prescriby is to become the standardized protocol layer that primary care clinics, pain clinics, and addiction-adjacent specialists use whenever they prescribe an opioid or initiate a taper. The category has the structural features that produce category-defining companies: a high-stakes clinical workflow, regulatory pressure pushing buyers toward standardization, settlement money flowing into prevention budgets, and an absence of an obvious incumbent specifically built for the prevention use case [EU-Startups, April 2024] [ArcticStartup]. The Crowberry-led syndicate's willingness to back the company across three countries at seed stage suggests the thesis is reachable rather than purely aspirational [Northstack].

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Settlement-funded state contract	A US state health agency adopts Prescriby as the prescribing-prevention tool funded by opioid settlement dollars	A reference deployment in Maine that produces measurable reductions in long-term opioid use [Mainebiz]	Maine and other heavily-affected states are actively allocating settlement funds to prevention infrastructure
Nordic public-health rollout	A Nordic national health system standardizes on Prescriby for addictive-medication oversight	Crowberry-led syndicate opens doors to Icelandic and Danish health authorities [EU-Startups, April 2024]	The investor base is regionally embedded and the European prescribing posture favors structured tools
EHR integration partnership	Prescriby becomes the embedded tapering protocol inside one or more regional EHR platforms	A commercial partnership rather than head-on competition with EHR vendors	Avoiding direct competition with EHRs is the path most specialty clinical tools have taken to scale

What compounding looks like. The flywheel for a clinical workflow tool of this kind is outcomes data. Each clinic deployment generates prescribing and tapering data that, when aggregated and published, strengthens the protocol library and the evidence base for the next sale. The Maine tapering clinic is the early version of that loop: a directly-operated site producing the kind of structured outcomes evidence that purely software-only competitors cannot easily generate [Mainebiz]. If that data translates into peer-reviewed publications and payer-recognized quality measures, the cost of switching away from Prescriby compounds for every additional clinic on the platform.

The size of the win. Comparable public-market and acquisition benchmarks for clinical workflow software in regulated specialties have historically supported nine and ten-figure outcomes when the company becomes the de facto standard for a clinical use case. A credible scenario, not a forecast, would put Prescriby on a path to a Series A in the next 12 to 24 months if it can show two to three reference deployments with retention and outcomes data, and on a path to category leadership over a longer horizon if the settlement-funded state contract scenario plays out. The public record today supports the seed-stage thesis; the next round will turn on evidence the team has not yet had time to produce.

Data Accuracy: YELLOW -- Scenarios are analytical extrapolations from cited funding, clinic, and market evidence; outcome figures are scenario-based and not forecasts.

Sources

PUBLIC

1. [EU-Startups, April 2024] Icelandic startup Prescriby secures €2 million in funding to innovate at the root of the opioid crisis | https://www.eu-startups.com/2024/04/icelandic-startup-prescriby-secures-e2-million-in-funding-to-innovate-at-the-root-of-the-opioid-crisis/

2. [Crunchbase] Prescriby - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/prescriby

3. [PitchBook] Prescriby 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/502706-62

4. [ArcticStartup] Icelandic-Canadian Prescriby secures €2M funding to lead proactive fight against opioid crisis | https://arcticstartup.com/prescriby-raises-e2m/

5. [Northstack] Prescriby raises a $2.1M round led by Crowberry Capital | https://www.northstack.is/prescriby/

6. [LinkedIn] Prescriby company page | https://is.linkedin.com/company/prescriby

7. [Mainebiz] Icelandic firm sets up 'tapering clinic' in Maine | https://mainebiz.biz/article/icelandic-firm-sets-up-tapering-clinic-in-maine/

8. [LinkedIn] Kjartan Thorsson - Prescriby | https://www.linkedin.com/in/kjartanthors/